These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29575770)

  • 21. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
    Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
    J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.
    Blanchette VS; Zunino L; Grassmann V; Barnes C; Carcao MD; Curtin J; Jackson S; Khoo L; Komrska V; Lillicrap D; Morfini M; Romanova G; Stephens D; Zapotocka E; Rand ML; Blatny J
    Thromb Haemost; 2021 Oct; 121(10):1326-1336. PubMed ID: 33506480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
    Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
    J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
    Takedani H; Hirose J
    Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
    Oldenburg J; Windyga J; Hampton K; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
    Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
    Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S
    Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.
    Hyun SY; Park SY; Lee SY; Kook H; Paik SH; Jang IJ; Lee KS
    Yonsei Med J; 2015 Jul; 56(4):935-43. PubMed ID: 26069114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.
    Frampton JE; Wagstaff AJ
    Drugs; 2008; 68(6):839-53. PubMed ID: 18416588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind.
    Hermans C; Pierce GF
    J Thromb Haemost; 2024 Jul; 22(7):1844-1846. PubMed ID: 38679336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of being overweight on factor VIII dosing in children with haemophilia A.
    Henrard S; Hermans C
    Haemophilia; 2016 May; 22(3):361-7. PubMed ID: 26558443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.